Transparency Market Research (TMR) has
published a new report on the global gemcitabine
HCl market for the
forecast period of 2019 to 2027. According to the report, the global
gemcitabine HCl market is projected to reach a value of over US$ 900 Mn by
2027, expanding at a CAGR of nearly 7% from 2019 to 2027. Initiatives by key
players, and the growing number of patient support organizations and
governmental & healthcare agencies to spread awareness regarding cancer is
projected to drive the global gemcitabine HCl market. Technical advancements in
the manufacturing of generic drugs have also led to an increase in the demand
for gemcitabine HCl, which is expected to propel the global gemcitabine HCl
market in the near future.
Request a PDF Sample
- https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=67622
Gemcitabine HCl
Market: Overview
·
The gemcitabine HCl market report offers exhaustive
segmentation of the global market based on type, application, and end user. In
terms of type, the gemcitabine HCl market has been segmented into branded and
generic. The generic segment held a major share in the gemcitabine HCl market
in 2018. Low cost, similar efficacy, and increase in the demand for generic
drugs are the factors driving this segment in the global gemcitabine HCl
market.
·
Based on application, the global gemcitabine HCl market
has been classified into pancreatic cancer, breast cancer, ovarian cancer,
non-small-cell lung carcinoma (NSCLC), and others. The pancreatic cancer
segment held a leading market share in 2018, owing to increased incidences of
this disease. Pancreatic cancer usually affects the geriatric population.
Increase in the geriatric population is one of the factors fueling the growth
of this segment in the global gemcitabine HCl market.
Enquiry Before Buying Gemcitabine HCL Market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=67622
·
In terms of end user, the global gemcitabine HCl market
has been divided into hospitals, cancer centers, and others. The hospitals
segment is anticipated to grow at a rapid pace in the next few years. The
adoption of healthcare information systems in hospitals is rising in Asia
Pacific due to an increase in the number of private sector hospitals in the
region. This, in turn, is likely propel the gemcitabine HCl market in the next
few years.
·
Geographically, the global gemcitabine HCl market has
been segmented into North America, Europe, Asia Pacific, Latin America, and the
Middle East & Africa, North America and Asia Pacific gemcitabine HCl
markets are anticipated to drive global demand. The gemcitabine HCl market in
North America is expected to expand at a high CAGR from 2019 to 2027. This is
attributed to the adoption of cost-effective genetic drugs, expiry of patented
products, proper guidelines for the manufactures of biosimilars, and the
presence of a large number of players in the generics market in the region.
·
The demand for cost-effective generic cancer drugs is
rising, especially in emerging countries such as China, India, and Brazil. This
is due to the increase in the incidences of cancer and a surge in the
acceptance of generic drugs in the global gemcitabine HCl market.
Request For Discount - https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=67622
Generic Segment
Expected to Grow at a Rapid Pace in the Gemcitabine HCl Market
·
The report offers exhaustive segmentation of the global
gemcitabine HCl market based on type, application, and end user. In terms of
type, the gemcitabine HCl market has been segmented into generic and branded.
·
The generic segment held a major share in the gemcitabine
HCl market in 2018. This segment is likely to grow at a rapid pace in the next
few years, attributed to the strong pipeline of generic gemcitabine HCl drugs.
In order to market a generic drug, a company needs to file an Abbreviated New
Drug Application (ANDA). An ANDA approval implies that the generic drug is
comparable to the original drug in terms of strength, dosage form and quality,
route of administration, performance, characteristics, and intended use.
·
However, companies cannot manufacture a generic unless
the patent of a drug expires. After the patent loss of Gemzar in 2010, several
generics have entered the gemcitabine HCl market. The demand for low-cost
substitutes of gemcitabine HCl is high in low- and middle-income countries in
the Asia Pacific, Africa, and Latin America gemcitabine HCl markets.
·
This has increased the number of gemcitabine API
manufacturers, since pharmaceutical drug manufacturers do not have enough
in-house capacity to meet the demand.
Request for Analysis of COVID19 Impact on Gemcitabine HCL
Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=67622
Pancreatic Cancer
& Hospitals Segments to Capture Prominent Market Shares
·
The pancreatic cancer segment held a major market share
in 2018, owing to the rise in incidences of pancreatic cancer. According to
WHO, there will be nearly 638,647 new cases of pancreatic cancer in 2030, as
against 458,918 in 2018.
·
This increase in the number of cases is primarily due to
the increasing geriatric population, and the associated risk factors becoming
increasingly common among the population. This is expected to drive the global
gemcitabine HCl market in the new few years.
·
The hospitals segment is expected to grow at a rapid pace
in the next few years. Hospitals provide low-cost treatment to all citizens
across the globe.
·
Strategic collaborations with hospitals for cancer
research studies on several hundred patients with a variety of cancer types
have helped companies come up with novel drugs and therapeutic treatments.
·
The hospital infrastructure in emerging countries is
developing at a significant pace, as various regional and national governments
(for example Saudi Arabia) are encouraging private players to enter the
healthcare services sector.
Request For Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=67622
Asia Pacific
Gemcitabine HCl Market Expected to Expand at a High CAGR
·
North America is likely to be a prominent region in the
global gemcitabine HCl market during the forecast period. Easy adoption of new
products, presence of key players, and favorable reimbursement policies are
attributed to the region’s dominance in the global gemcitabine HCl market. The
gemcitabine HCl markets in Europe and Asia Pacific are also projected to grow
at a rapid pace from 2019 to 2027.
·
The gemcitabine HCl market in these regions are
anticipated to be driven by the rise in the demand for cost-effective generic
cancer drugs, especially in emerging countries such as China, India, and
Brazil, due to an increase in the incidences of cancer and a surge in the
acceptance of generic drugs. Additionally, India- and China-based drug
manufacturers have a strong presence in the global gemcitabine HCl market.
Gemcitabine API manufacturers in India have been investing to comply with U.S.
FDA regulations and to win contracts from U.S.-based companies, and have been
filing DMF applications. This is expected to boost the global gemcitabine HCl
market in the coming years.
·
Additionally, initiatives by key players, patient support
organizations, and governmental & healthcare agencies to spread awareness
about cancer are expected to boost the growth of the gemcitabine HCl market in
these regions. Technical advancements in the manufacture of generic drugs have
also led to an increase in the demand for gemcitabine HCl, which is expected to
propel the global gemcitabine HCl market in the near future.
Buy now Gemcitabine HCL Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=67622<ype=S
Gemcitabine HCl
Market: Competitive Landscape:
·
Major players operating in the global gemcitabine HCl
market include Teva Pharmaceutical Industries Ltd., Lupin Ltd., Sanofi, Biocon.
Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries Ltd., Mylan N.V.,
GlaxoSmithKline plc, and AstraZeneca plc.
·
Launch of new products, focus on development of
technologically-advanced products by companies, and product approvals are
expected to drive the global gemcitabine HCl market during the forecast period.
More Trending
Reports by Transparency Market Research:
https://www.prnewswire.com/news-releases/companies-in-smart-healthcare-products-market-collaborate-with-health-stakeholders-to-reduce-burden-of-chronic-diseases-global-valuation-to-expand-at-8-8-from-2019-to-2027-tmr-301325980.html
https://www.prnewswire.com/news-releases/focus-on-patients-welfare-spurs-sales-in-clinical-laboratory-services-market-mounting-burden-of-infectious-diseases-present-potential-revenue-streams-tmr-301331485.html
https://www.prnewswire.com/news-releases/implantable-cardiac-monitor-market-to-thrive-on-increasing-incidence-of-cardiac-arrhythmias-technological-innovations-to-present-better-treatment-opportunities-for-geriatric-population-with-cardiac-conditions-tmr-301262941.html
About Us
Transparency Market
Research is a global market intelligence company, providing global business
information reports and services. Our exclusive blend of quantitative
forecasting and trends analysis provides forward-looking insights for thousands
of decision-makers. Our experienced team of analysts, researchers, and
consultants use proprietary data sources and various tools and techniques to
gather and analyze information.
Our data repository is
continuously updated and revised by a team of research experts, so that it
always reflects the latest trends and information. With a broad research and
analysis capability, Transparency Market Research employs rigorous primary and
secondary research techniques in developing distinctive data sets and research
material for business reports.
Contact
Transparency Market Research,
90 Sate Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.Transparencymarketresearch.com/
